Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 4:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Eplerenone Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Hypoglycemia and the Mineralocorticoid Receptor

NCT01394627
View directory record Official record
Conditions
Hypoglycemia
Interventions
Eplerenone, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Jun 7, 2026, 4:38 AM EDT
Completed Phase 4 Interventional

Aldosterone Antagonism in Diastolic Heart Failure

NCT00108251
View directory record Official record
Conditions
Congestive Heart Failure, Diastole
Interventions
Eplerenone, Placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Jun 7, 2026, 4:38 AM EDT
Completed Not applicable Interventional Results available

Eplerenone for the Treatment of Central Serous Chorioretinopathy

NCT01990677
View directory record Official record
Conditions
Central Serous Chorioretinopathy
Interventions
25mg Eplerenone, Placebo
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
10
States / cities
Cherry Hill, New Jersey • Marlton, New Jersey • Mays Landing, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Jun 7, 2026, 4:38 AM EDT
Recruiting Phase 4 Interventional

Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study

NCT05030545
View directory record Official record
Conditions
Primary Aldosteronism, Hypertension
Interventions
Eplerenone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Jun 7, 2026, 4:38 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension

NCT01996449
View directory record Official record
Conditions
Hypertension
Interventions
Eplerenone, Amlodipine, Microneurography, Rhythmic handgrip exercise, Sustained hand grip, Forearm blood flow, Arm cycling exercise, Cold Pressor test
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Jun 7, 2026, 4:38 AM EDT
Withdrawn Phase 4 Interventional

CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy Regression

NCT01275352
View directory record Official record
Conditions
Hypertension
Interventions
Eplerenone, placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Jun 7, 2026, 4:38 AM EDT
Completed Not applicable Interventional Results available

Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy

NCT01521546
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
eplerenone, placebo
Drug
Lead sponsor
Subha Raman
Other
Eligibility
7 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Jun 7, 2026, 4:38 AM EDT
Withdrawn Phase 4 Interventional

Effect of Eplerenone on Novel Biomarkers of Mineralocorticoid Receptor Activation (ENOVA)

NCT04746495
View directory record Official record
Conditions
Hypertension
Interventions
Placebo, Eplerenone 50mg
Drug
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Jun 7, 2026, 4:38 AM EDT
Completed Phase 4 Interventional Results available

Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism

NCT02034435
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Low Salt diet plus Placebo tablet, Low Sodium diet plus Salt tablet, Epleronone, Amlodipine
Other · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Jun 7, 2026, 4:38 AM EDT
Completed Phase 3 Interventional Results available

A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines

NCT00232180
View directory record Official record
Conditions
Heart Failure
Interventions
Eplerenone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
55 Years and older
Enrollment
2,743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
51
States / cities
Phoenix, Arizona • Loma Linda, California • Merced, California + 37 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Jun 7, 2026, 4:38 AM EDT
Completed Early Phase 1 Interventional Results available

Pressure Assessment to Improve Outcomes After TAVR: a Registry

NCT03923530
View directory record Official record
Conditions
Hypertension, Aortic Stenosis, Calcific, Quality of Life, Heart Failure With Preserved Ejection Fraction
Interventions
Eplerenone
Drug
Lead sponsor
North Florida Foundation for Research and Education
Other
Eligibility
55 Years to 100 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Jun 7, 2026, 4:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Eplerenone on Postprandial Inflammatory Response in Healthy Adults

NCT01786551
View directory record Official record
Conditions
Systemic Proinflammatory State
Interventions
Eplerenone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Jun 7, 2026, 4:38 AM EDT
Completed Phase 4 Interventional Results available

Diurnal Variation of Plasminogen Activator Inhibitor-1

NCT00515021
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Eplerenone (Morning), Eplerenone (Night-time)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Jun 7, 2026, 4:38 AM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Jun 7, 2026, 4:38 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension

NCT00758524
View directory record Official record
Conditions
Essential Hypertension
Interventions
LCI699, Eplerenone, LCI699-matching Placebo, Eplerenone-matching Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Jun 7, 2026, 4:38 AM EDT
Terminated Phase 2 Interventional Results available

Cardiometabolic Effects of Eplerenone in HIV Infection

NCT02629094
View directory record Official record
Conditions
Cardiac Steatosis, Hepatic Steatosis
Interventions
Inspra /Eplerenone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Jun 7, 2026, 4:38 AM EDT
Completed Phase 4 Interventional Results available

EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia

NCT00187889
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
Eplerenone, Placebo or sugar pill
Drug
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2013 · Synced Jun 7, 2026, 4:38 AM EDT
Withdrawn Phase 4 Interventional

Detection of Diffuse Scar in Patients With Diabetes

NCT01794091
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Eplerenone, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jun 7, 2026, 4:38 AM EDT
Terminated Phase 4 Interventional

Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure

NCT00293150
View directory record Official record
Conditions
Diastolic Heart Failure
Interventions
Eplerenone
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Jun 7, 2026, 4:38 AM EDT
Completed Phase 4 Interventional

The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure

NCT00082589
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
Eplerenone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
53
States / cities
Castro Valley, California • San Diego, California • Santa Rosa, California + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Jun 7, 2026, 4:38 AM EDT
Completed Phase 3 Interventional

The Long-term Study to Evaluate the Safety of Eplerenone in the Treatment of Hypertension in Children Aged 6 to 16 Years

NCT00147615
View directory record Official record
Conditions
Hypertension
Interventions
Eplerenone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
6 Years to 16 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
7
States / cities
Los Angeles, California • Park Ridge, Illinois • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Jun 7, 2026, 4:38 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)

NCT04300881
View directory record Official record
Conditions
Vitreomacular Traction, Subretinal Edema
Interventions
Eplerenone
Drug
Lead sponsor
Wagner Macula & Retina Center
Other
Eligibility
19 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Jun 7, 2026, 4:38 AM EDT
Completed Phase 4 Interventional

Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity

NCT04519164
View directory record Official record
Conditions
Metabolic Syndrome, Hypertension, Overweight and Obesity
Interventions
Eplerenone, Chlorthalidone with potassium chloride
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jun 7, 2026, 4:38 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Eplerenone in the Treatment of Hypertension in Children.

NCT00147589
View directory record Official record
Conditions
Hypertension
Interventions
Eplerenone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
6 Years to 16 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
28
States / cities
Little Rock, Arkansas • Beverly Hills, California • Inglewood, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Jun 7, 2026, 4:38 AM EDT